Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment.

Baldassarri SR, Beitel M, Zinchuk A, Redeker NS, Oberleitner DE, Oberleitner LMS, Carrasco D, Madden LM, Lipkind N, Fiellin DA, Bastian LA, Chen K, Yaggi HK, Barry DT. Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment. Sleep & Breathing = Schlaf & Atmung. 2020 Dec 1; 24(4):1729-1737.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

PURPOSE: The aim of this study was to evaluate the prevalence and clinical correlates of impaired sleep quality and excessive daytime sleepiness among patients receiving methadone for opioid use disorder (OUD). METHODS: Patients receiving methadone (n  = 164) completed surveys assessing sleep quality (Pittsburgh Sleep Quality Index [PSQI]), daytime sleepiness (Epworth Sleepiness Scale [ESS]), and related comorbidities. We used bivariate and multivariable linear regression models to evaluate correlates of sleep quality and daytime sleepiness. RESULTS: Ninety percent of patients had poor sleep quality (PSQI > 5), and the mean PSQI was high (11.0 ±4). Forty-six percent reported excessive daytime sleepiness (ESS > 10). In multivariable analyses, higher PSQI (worse sleep quality) was significantly associated with pain interference (coefficient? = 0.40; 95% CI? = 0.18-0.62; ß? = 0.31), somatization (coefficient? = 2.2; 95% CI? = 0.75-3.6; ß? = 0.26), and negatively associated with employment (coefficient? = -?2.6; 95% CI? = -?4.9 to -?0.19; ß? = -?0.17). Greater sleepiness was significantly associated with body mass index (coefficient? = 0.32; 95% CI? = 0.18-0.46; ß? = 0.33), and there was a non-significant association between sleepiness and current chronic pain (coefficient? = 1.6; 95% CI? = 0.26-3.5; ß? = 0.13; p value? = 0.09). CONCLUSIONS: Poor sleep quality and excessive daytime sleepiness are common in patients receiving methadone for OUD. Chronic pain, somatization, employment status, and obesity are potentially modifiable risk factors for sleep problems for individuals maintained on methadone. People with OUD receiving methadone should be routinely and promptly evaluated and treated for sleep disorders.